Results 61 to 70 of about 30,645 (194)
Functionally cured chronic hepatitis B: A cure‐related occult HBV infection state
Abstract Occult HBV infection (OBI) is characterized by the presence of replication‐competent hepatitis B virus (HBV) DNA (covalently closed circular DNA [cccDNA] and/or relaxed circular DNA [rcDNA]) in the liver and/or HBV DNA in the blood, despite negative hepatitis B surface antigen (HBsAg) serology.
Fengmin Lu +6 more
wiley +1 more source
Forest Plot for HBeAg Seroconversion when ETV was used as the Control Group.
Forest Plot for HBeAg Seroconversion when ETV was used as the Control Group.
Qiao-Ling Xie (777501) +4 more
core +1 more source
TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. [PDF]
The immune mechanisms underlying failure to achieve hepatitis B e antigen (HBeAg) seroconversion associated with viral control in chronic hepatitis B (CHB) remain unclear.
Qintao Lai +11 more
doaj +1 more source
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source
ABSTRACT Introduction HIV pre‐exposure prophylaxis (PrEP) users may be disproportionately vulnerable to sexually transmitted infections (STIs) in general, including several that are vaccine‐preventable. Understanding immunization patterns in this population is, therefore, crucial. However, data on vaccination coverage among Brazilian PrEP users remains
Marjorie Marini Rapozo +6 more
wiley +1 more source
Odds ratios of HBeAg seroconversion after 2-year treatment as revealed by network meta-analysis.
Odds ratios of HBeAg seroconversion after 2-year treatment as revealed by network meta-analysis.
Lin Cao (294505) +3 more
core +1 more source
Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up
The aim of treatment of chronic hepatitis B with interferon is to induce a transition from the replicative phase of the disease to a nonreplicative state, with loss of hepatitis B virus (HBV)-DNA, seroconversion from hepatitis B e antigen (HBeAg ...
Jean-Pierre Villeneuve, Bernard Willems
doaj +1 more source
Evolving Strategies in HBV Management: Insights From Updated International Guidelines
Recent updates to WHO (2024), EASL (2025), and AASLD (2025) hepatitis B guidelines reflect divergent strategies, ranging from simplified public health‐oriented treatment expansion to biomarker‐driven precision medicine. Despite differences in treatment eligibility and nucleos(t)ide analogue discontinuation, all guidelines converge on early intervention
Masaru Enomoto +3 more
wiley +1 more source
Cumulative HBeAg seroconversion rates in survivors of infantile fulminant/non-fulminant hepatitis B (N = 9).
Fu-Chang Hu (177537) +11 more
core +1 more source
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki +7 more
wiley +1 more source

